The presence of SARS-CoV2 antibodies in MS patients

Mult Scler Relat Disord. 2021 May:50:102793. doi: 10.1016/j.msard.2021.102793. Epub 2021 Jan 23.

Abstract

Background: The COVID-19 pandemic has raised novel concerns for people living with MS regarding their safety.

Methods: Observational study of patients at a single comprehensive community MS center.

Results: 48 patients with MS were suspected of developing COVID-19 March to May 2020; 2 died. Of the remainder, 17 were tested for COVID-19 antibodies as part of routine care. Average age of this subgroup was 49.8y ± 11.3 (age range 32-67), 76% female. 65% were treated with an anti-CD20 drug, 12% untreated, and 6% each received glatiramer acetate, interferon, natalizumab, or teriflunomide. 59% of patients were antibody negative.

Conclusions: The low incidence of SARS CoV2 antibodies following infection suggests that certain DMTs may alter SARS CoV2-Ab response or persistence.

Keywords: Anti-B cell treatment; COVID-19; COVID-19 antibodies; Disease modifying treatment; MS; Observational study.

Publication types

  • Letter
  • Observational Study

MeSH terms

  • Adult
  • Aged
  • COVID-19*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis* / epidemiology
  • Pandemics
  • RNA, Viral
  • SARS-CoV-2

Substances

  • RNA, Viral